Vertex Flooring introduces distinctive marquetry flooring crafted with expert precision, offering custom wood designs ...

Why the Vertex Price Target Just Got Tweaked The small lift in Vertex Pharmaceuticals' fair value estimate to US$496.16 per ...

In the latest close session, Vertex Pharmaceuticals (VRTX) was down 1.24% at $463.86. This change lagged the S&P 500's daily ...

Vertex Pharmaceuticals is anchored by cystic fibrosis as launches lag, JOURNAVX and CASGEVY add little revenue, and growth is ...

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $469.68, marking a -2.99% move from the previous day.

While I believe Pfizer will rebound eventually, it will take some time to do so, and it may not occur in 2026. In the meantime, other healthcare leaders could perform significantly better this year ...

Vertex Pharmaceuticals (VRTX) is back in focus after Wolfe Research upgraded the stock to Outperform, citing increased ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks ...

For Vertex these days, it’s all about the launches of three new products—sickle cell disease gene therapy Casgevy, the company’s fifth cystic fibrosis treatment Alyftrek and its non-opioid pain relief ...